Project Grant HT94252510540
Award Date
7/15/25
Completion Date
7/14/27
Dollars Obligated
$624K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $1,100,747.00 to the Regents of the University of Michigan to conduct research on "PROTEIN ENGINEERING OF ANTIBODY-DRUG CONJUGATES TO COORDINATE THE INNATE AND ADAPTIVE IMMUNE SYSTEMS FOR CURATIVE RESPONSES." The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative biomedical...
The Defense Health Agency awarded a $1,178,939.00 Project Grant to the Regents of the University of Michigan under the Military Medical Research and Development program (CFDA 12.420) to conduct advanced phenotyping research to improve diagnostic, longitudinal assessment, and treatment strategies for deployment-related respiratory disease. The award period is from September 1, 2023 to August 31, 2026. As a U.S. Government Entity and top public research university, the University of Michigan has...
The Defense Health Agency awarded a $607,377 Project Grant to the Regents of the University of Michigan to fund a 2-year research project titled "A NEW IDEA FOR ADVANCING AXITINIB-BASED THERAPY IN RECURRENT AND METASTATIC HNSCC." This grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform healthcare for service members and the public. The University of Michigan, a leading...
This Project Grant award of $546,000.00 from the Defense Health Agency supports research at the Regents of the University of Michigan to develop a novel lectin for targeting T-cell lymphomas. The award is part of the Military Medical Research and Development program (CFDA 12.420), which funds basic, applied, and advanced biomedical research to transform healthcare for service members and the public through innovative and impactful research. The 3-year award began on September 1, 2023 and will...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,844,306.00 Project Grant to the Regents of the University of Michigan on September 1, 2025. The grant, titled "COTARGETING NSD1/2 PARALOGS IN AR-DRIVEN CASTRATION-RESISTANT PROSTATE CANCER," will support advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The research will investigate innovative medical...
The Regents of the University of Michigan received a $312,000.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The 2-year grant, awarded on February 1, 2024, supports research to investigate "An Unexpected Role for the Ubiquitin Proteasome System in Repeat Associated Non-AUG Translation." This basic and translational biomedical research aims to advance understanding and treatment of neurological disorders...
This $1,248,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will support the "RARE-CANCER COMMONS: A HUB FOR ACCELERATING INDIVIDUALIZED RARE CANCER THERAPY THROUGH INTEGRATION OF SINGLE-CELL AND CLINICAL GENOMICS DATA" research initiative at the University of Michigan. The project, running from November 1, 2024 to October 31, 2027, will leverage the University's extensive research capabilities to...
This $1,404,000.00 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program to the Regents of the University of Michigan, Office of Research and Sponsored Projects (doing business as the University of Michigan) on September 1, 2023. The funding will support research to target the lipid kinase PIKfyve in neuroendocrine prostate cancer over a 3-year period ending on August 31, 2026. The University of Michigan is a leading U.S....
This $1,248,000 Cooperative Agreement award from the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program supports the University of Michigan's "Phase 1/2 Clinical Trials Assessment in Kidney Cancer Therapeutics (U-MPAKT)" project. The award, effective September 15, 2024 through September 14, 2028, will fund the university's advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $467,742 Project Grant to the Regents of the University of Michigan to optimize a risk stratification model for ovarian cancer. The award will support research activities from September 1, 2024 through August 31, 2026. The University of Michigan, a top public research institution, has extensive experience conducting federal research and development projects for agencies such as the...